Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow bank, announced today the launch of a new program that further expands patient access to Ossium's bone marrow.

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow bank, announced today the launch of a new program that further expands patient access to Ossium’s bone marrow. Through the HOPE (HPC Offered for PRESERVE Expansion) Program, patients that need an allogeneic bone marrow transplant but are ineligible to participate in Ossium’s active clinical study (PRESERVE I) have a new opportunity to receive bone marrow from Ossium’s bank. The goal of Ossium’s PRESERVE trials is to establish organ donor bone marrow as a new source of stem cells for hematologic reconstitution and unlock access to stem cell transplants for the thousands of patients who search unsuccessfully for a donor each year. The company recently initiated the PRESERVE I clinical study and is currently enrolling patients at five transplant centers across the United States. Through PRESERVE I, 12 patients with acute leukemias will receive a transplant with bone marrow from Ossium’s bank, generating the safety and efficacy data required to initiate a long-term phase 2 study (PRESERVE II). Ossium launched the HOPE Program after recognizing the sheer volume of patients that need a bone marrow transplant but are unable to participate in the PRESERVE I study due to its eligibility criteria or the patient’s geography

Ossium Health launches HOPE Program to give all patients hope for a cure.